Pfizer Inc.(PFE)Earnings, Financials & Key RatiosPfizer Inc. (PFE) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the erratic OCF/NI ratio, which swung from -74.21 in 2024Q2 to 16.68 in 2024Q4, warrants caution regarding the quality of underlying earnings.
Pfizer Inc. (PFE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Pfizer Inc. (PFE) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.75vs $0.72+3.9% | $14.5Bvs $13.8B+4.4% |
| Q1 2026 | Feb 3, 2026 | $0.66vs $0.57+16.4% | $17.6Bvs $16.8B+4.2% |
| Q4 2025 | Nov 4, 2025 | $0.87vs $0.63+37.4% | $16.7Bvs $16.5B+0.9% |
| Q3 2025 | Aug 5, 2025 | $0.78vs $0.58+34.5% | $14.7Bvs $13.6B+8.1% |
Recent stock market news and headlines for Pfizer Inc. (PFE)
Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a preliminary review to be potentially included in China's basic medical insurance drug catalogue, a a list published by the National Healthcare Security Administration showed on Monday.
One of Pfizer's promising oncology candidates recently failed a phase 3 study. The drugmaker is also losing its CFO.
Pfizer is one of the world's largest drug companies. It has a long history of navigating the industry's ups and downs.
Pfizer's high yield is the result of the stock's lingering underperformance, reflecting one serious concern. To circumvent this headwind, the company has been rebuilding and continues to rebuild itself.
When Pfizer was coming out of the COVID-induced growth phase in early 2024, I turned bullish alongside CEO Albert Bourla, effectively betting his pension on Pfizer stock. Since then, Pfizer has proven to be a drag on my portfolio returns, but I have found good enough reasons to remain bullish. One of the biggest drags on Pfizer stock has been rising investor concerns over Pfizer's ability to bridge revenue losses arising from patent expiry with new drugs.
Key metrics vs top competitors for Pfizer Inc. (PFE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $24.07 | $136.92B | 17.70 | -1.65% | 12.42% | 8.87% | 7.14% | |
| $267.24 | $643.31B | 24.23 | 6.05% | 21.83% | 26.26% | — | |
| $128.86 | $318.26B | 17.70 | 1.18% | 13.62% | 17.91% | — | |
| $254.65 | $449.91B | 107.45 | 8.57% | 5.79% | 67.46% | — | |
| $1235.56 | $1.17T | 53.84 | 44.7% | 34.98% | 101.17% | — | |
| $57.97 | $118.36B | 16.80 | -0.22% | 15.01% | 38.96% | — |
Pfizer Inc. (PFE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Pfizer Inc. (PFE) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Apr 27, 2026·SEC
Feb 3, 2026·SEC
Get notified when PFE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Pfizer Inc. (PFE) stock FAQ — growth, dividends, profitability & financials explained
Pfizer Inc. (PFE) reported $63.31B in revenue for fiscal year 2025. This represents a 460% increase from $11.31B in 1996.
Pfizer Inc. (PFE) saw revenue decline by 1.6% over the past year.
Yes, Pfizer Inc. (PFE) is profitable, generating $7.49B in net income for fiscal year 2025 (12.4% net margin).
Yes, Pfizer Inc. (PFE) pays a dividend with a yield of 7.14%. This makes it attractive for income-focused investors.
Pfizer Inc. (PFE) has a return on equity (ROE) of 8.9%. This is below average, suggesting room for improvement.
Pfizer Inc. (PFE) generated $9.48B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
